Australia markets closed

Inovio Pharmaceuticals, Inc. (0A43.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
1.9900+0.0200 (+1.02%)
As of 07:13PM BST. Market open.
Full screen
Previous close1.9700
Open1.9100
Bid0.0000 x N/A
Ask0.0000 x N/A
Day's range1.8900 - 2.0100
52-week range1.8900 - 2.0100
Volume5,204
Avg. volumeN/A
Market capN/A
Beta (5Y monthly)0.65
PE ratio (TTM)N/A
EPS (TTM)-1.4540
Earnings date08 Aug 2022 - 12 Aug 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Motley Fool

    Is This Vaccine Stock in Trouble -- or Ready for a Rebound?

    In the early days of the coronavirus vaccine race, Inovio Pharmaceuticals (NASDAQ: INO) was one of the favorites. One major headwind slowed things down: The U.S. Food and Drug Administration (FDA) placed Inovio's coronavirus vaccine trial on a partial clinical hold in late 2020. Does all of this mean Inovio is in trouble?

  • Zacks

    Inovio Pharmaceuticals (INO) Reports Q1 Loss, Lags Revenue Estimates

    Inovio (INO) delivered earnings and revenue surprises of -28.57% and 56.26%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

  • PR Newswire

    INOVIO Reports First Quarter 2022 Financial Results and Program Developments

    INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and treat people with cancer and HPV-associated diseases, today reported financial results for the quarter ended March 31, 2022 and announced recent program and corporate developments. INOVIO's management will host a live conference call and webcast at 4:30 p.m. Eastern Time today to discuss financial results and provide a general business update.